Norway's 'Oslo patient' reaches HIV remission after rare stem cell transplant donated by brother
medicalxpress - A Norwegian man has been effectively cured of HIV after receiving a stem cell transplant from his brother, doctors announced on Monday.
AI Summary: A remarkable clinical case: a patient in Norway known as the "Oslo patient" has entered sustained HIV remission following a rare stem‑cell transplant from a donor with genetic resistance to the virus. The outcome offers cautious optimism for curative strategies, though experts stress this remains an exceptional, high‑risk intervention rather than a broadly applicable cure.
Anti-amyloid Alzheimer's drugs show no clinically meaningful effect
medicalxpress - Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new review in the Cochrane Database of Systematic Reviews has found.
AI Summary: A major review concludes anti-amyloid Alzheimer’s medications show no clinically meaningful effect on patients’ cognition or daily function, prompting renewed debate about drug approvals, prescribing and research priorities. The analysis calls for careful reassessment of treatment value, clearer communication to patients and tighter scrutiny of future trials.
- Anti-amyloid drugs fall short: little benefit, safety risks (5)
- New biomarkers and imaging reshape Alzheimer’s diagnosis timing (3)
- Social and care issues: loneliness, memory and treatment decisions (2)
- All Other Stories
Anti-amyloid drugs fall short: little benefit, safety risks
New biomarkers and imaging reshape Alzheimer’s diagnosis timing
Social and care issues: loneliness, memory and treatment decisions
All Other Stories
Scientists finally uncover why promising cancer drugs keep failing
sciencedaily - Cancer drugs known as BET inhibitors once looked like a breakthrough, but in real patients they’ve often fallen short. New research reveals a key reason why: two closely related proteins, BRD2 and BRD4, don’t actually do the same job. Instead, BRD2 acts l…
AI Summary: Scientists uncovered a cellular survival mechanism that helps tumors withstand DNA damage, offering a concrete explanation for why numerous promising anti‑cancer agents stumble in clinical trials. The discovery exposes a resistance pathway that blunts drug efficacy and suggests new targets to sensitize tumors and potentially revive stalled therapies — which, yes, might finally save some development budgets.
- BET inhibitor paradox — BRD2 preps, BRD4 triggers gene activation (3)
- OTHER — Diverse resistance mechanisms and maps of tumor adaptation (6)
- Replication-fork rescue — Tumors patch DNA breaks to survive therapy (3)
- RNA regulation vulnerabilities — RNA editing and noncoding RNAs expose targets (3)
- All Other Stories
BET inhibitor paradox — BRD2 preps, BRD4 triggers gene activation
OTHER — Diverse resistance mechanisms and maps of tumor adaptation
Replication-fork rescue — Tumors patch DNA breaks to survive therapy
RNA regulation vulnerabilities — RNA editing and noncoding RNAs expose targets
All Other Stories
Oricell Lands $110M to Take Cell Therapy to New Territory in Cancer
Frank Vinluan / medcitynews - There are no FDA-approved therapies for GPC3, a protein highly expressed by liver cancers. Oricell Therapeutics claims its cell therapy could be best in this class, but it faces competition from companies such as AstraZeneca and Eureka Therapeutics. The p…
AI Summary: Oricell, a China‑based CAR‑T developer, secured fresh financing to accelerate its cell‑therapy programs and support plans to go public. The fundraising will bankroll clinical expansion, manufacturing scale‑up, and regulatory preparations as the company pushes toward broader development and an IPO ambition, positioning it to compete in the crowded CAR‑T market.
Skin protein K16 found to control inflammation in stressed skin
medicalxpress - Keratin is the fibrous, waterproof protein that builds everything from our hair and nails to a rhino's horn. However, a tiny glitch in it can have problematic outcomes. A new study has found that changes in a keratin gene called KRT16 can lead to a rare c…
AI Summary: Researchers identified keratin 16 (K16) as a molecular brake on skin inflammation: loss of K16 ramps up interferon-driven immune signals, while its presence calms stressed keratinocytes. The discovery points to new targets for inflammatory skin disorders and suggests modulating K16 pathways could yield therapies that actually treat inflammation, not just slap on a cream.
An international mega-analysis of psychedelic drug effects on brain circuit function
Manesh Girn / nature - Nature Medicine, Published online: 06 April 2026; doi:10.1038/s41591-026-04287-9Analysis of neuroimaging datasets across five major psychedelics revealed a shared brain signature and provides a comprehensive insight into how these drugs reorganize brain a…
AI Summary: An international neuroimaging mega‑analysis traced psychedelic drugs’ effects on cortical networks, revealing consistent changes in brain connectivity that correlate with altered perception and cognition. The pooled study provides a stronger, replicated picture of how these compounds act on neural circuits, informing both therapeutic prospects and safety discussions.
Digital health startups raked in $4B during Q1 with 12 megadeals driving investment: Rock Health
fiercehealthcare - Digital health startups pocketed $4 billion in venture capital funding in the first quarter of 2026, marking the strongest first quarter since the pandemic peak.
AI Summary: Venture investment in digital health is narrowing: a small number of startups captured a large share of Q1 funding, driven by a handful of megadeals. The trend signals investor preference for later‑stage companies and scale plays, squeezing early innovators who must now demonstrate clearer paths to durable revenue and clinical impact.
Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine
Sophie Wedekind / cancerresearchuk - The Bowelbabe Fund has raised more that £20 million and has announced the next wave of funded projects, including the Bowelbabe Vaccine.The post Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine appeared first on Cancer Research U…
AI Summary: The Bowelbabe Fund celebrated a £20 million fundraising milestone and unveiled plans for a Bowelbabe Vaccine initiative, drawing high‑profile support. Organizers framed the cash infusion as a catalyst for prevention and research efforts, while public endorsements highlighted momentum — and the fundraising thermometer that finally stopped making them blush.
White House floats 12.5% budget cut for HHS in FY2027, reiterates reorganization plan
fiercehealthcare - The requested budget cut is about half of what the administration asked, and was denied, last year. However, plans for reorganizing agencies under an Administration for a Healthy America persist, as do calls to eliminate various programs and centers the W…
AI Summary: The administration has floated a plan to cut HHS funding by roughly 12–12.5% in FY2027 while pursuing agency reorganization. The proposal targets discretionary programs including research funding, prompting scientific groups to urge Congress to reject the NIH reductions and warn of downstream impacts on biomedical research and patient care.
- Researchers, cancer groups warn NIH cuts will harm patients (6)
- White House pushes deep HHS cuts, agency reorganization (4)
- All Other Stories
Researchers, cancer groups warn NIH cuts will harm patients
White House pushes deep HHS cuts, agency reorganization
All Other Stories
E.P.A. Targets Microplastics and Drugs in Drinking Water
Hiroko Tabuchi and Maxine Joselow / nytimes - The move drew praise from leaders of the Make America Healthy Again movement who had recently criticized the agency’s handling of toxic chemicals.
AI Summary: Federal agencies are moving from polite warnings to action on contaminants people actually drink. The EPA is targeting microplastics and trace pharmaceuticals in drinking water, while ARPA‑H is pouring funding into health-impact studies, and other agencies are considering formal contaminant designations to force testing, cleanup and new standards. Small particles, big headache.
WHOOP Secures $575M, Reaches $10B Valuation
Marissa Plescia / medcitynews - WHOOP’S Series G round was led by Collaborative Fund and includes participation from 2PointZero Group, Qatar Investment Authority, Cristiano Ronaldo and LeBron James.The post WHOOP Secures $575M, Reaches $10B Valuation appeared first on MedCity News.
AI Summary: Wearable fitness company Whoop closed a $575 million funding round that values the business at roughly $10 billion, attracting strategic partners including Abbott and health systems like Mayo Clinic. The cash infusion underwrites an aggressive hiring spree and product expansion as Whoop doubles down on clinical collaborations and scaling its sensor and analytics platform.
Eli Lilly Bets €2.4B on AI-Designed Drugs in New Insilico Medicine Deal
oncodaily - In a sweeping push to expand its pipeline and embrace artificial intelligence in drug discovery, Eli Lilly and Company has announced two major strategic moves: a multi-billion-dollar collaboration with Insilico […]
AI Summary: Eli Lilly struck a major partnership with Insilico Medicine to accelerate AI‑designed drug programs, providing a substantial upfront payment and committing to multiyear development milestones and potential payouts worth roughly in the billions. The deal expands Lilly’s AI drug discovery footprint and signals big pharma’s growing bet on algorithmic chemistry.
Kailera Plans IPO for Obesity Drug That Could Top Lilly’s Zepbound
Frank Vinluan / medcitynews - Kailera Therapeutics’ planned IPO will fund ongoing clinical development of a pipeline led by a drug that could rival Eli Lilly’s Zepbound in both efficacy and tolerability. Meanwhile, Renaissance Capital’s recap of first quarter 2026 IPOs shows slowing a…
AI Summary: Kailera announced plans for an initial public offering to fund late‑stage development of a Phase 3 obesity candidate licensed from Hengrui, positioning the program as a potential rival to Lilly’s Zepbound. The IPO aims to accelerate clinical work and commercial readiness as investors weigh market appetite for next‑generation weight‑loss therapies.
- Antimicrobial resistance risk found in South African wastewater (1)
- Financing rush: IPOs and venture cash fueling obesity drug race (4)
- New commercial models: subscriptions, telehealth, expanded patient access (4)
- Regulatory wins and science shaping next-generation weight-loss drugs (6)
- All Other Stories
Antimicrobial resistance risk found in South African wastewater
Financing rush: IPOs and venture cash fueling obesity drug race
New commercial models: subscriptions, telehealth, expanded patient access
Regulatory wins and science shaping next-generation weight-loss drugs
All Other Stories
Lost in space: Sperm struggles to navigate during weightless sex
medicalxpress - Scientists have used a tiny plastic "obstacle course" to test how much sperm would struggle to navigate during sex in the weightlessness of space.
AI Summary: New research shows sperm struggle to navigate and function in weightless conditions, suggesting microgravity could impair fertilization and complicate human reproduction beyond low-Earth orbit. Scientists warn these findings raise practical and biological questions for long-duration missions and potential colonization efforts, prompting calls for more reproductive biology studies in space.
J. Michael Bishop, Nobel Prize Winner for Cancer Research, Dies at 90
Delthia Ricks / nytimes - He helped discover cancer-causing genes. Later, as chancellor of the University of California, San Francisco, he led a major expansion.
AI Summary: J. Michael Bishop, Nobel Prize–winning cancer researcher, has died at 90. Colleagues recall his transformative work illuminating oncogenes and reshaping cancer biology, plus a career of mentorship that seeded generations of scientists. The obituaries and memorial pieces celebrate both his landmark discoveries and the enduring institutions and researchers he helped build.
Demoralized CDC Workforce Reels From Year of Firings, Funding Cuts, and a Shooting
Jess Mador, WABE / kffhealthnews - Thousands of employees are gone and last summer’s shooting resonates still at the Centers for Disease Control and Prevention headquarters and among the large public health community in Atlanta.
AI Summary: An internal crisis at the U.S. Centers for Disease Control has left staff demoralized after a year of firings, funding cuts and a workplace shooting. The acting chief vows to restore stability while the White House delays a permanent director nomination, prompting media scrutiny and debate over agency leadership and morale.
- Demoralized staff and leadership scramble at Atlanta's CDC (3)
- Inside the scramble for a permanent CDC director (3)
- Wider federal research cuts, RSV spread complicate CDC mission (3)
- All Other Stories
Demoralized staff and leadership scramble at Atlanta's CDC
Inside the scramble for a permanent CDC director
Wider federal research cuts, RSV spread complicate CDC mission
All Other Stories
Vivek Subbiah: New Nature Study on Thymic Health and Response
oncodaily - Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Wow published in NATURE journal ‘Thymic health and immunotherapy outcomes in patients […]
AI Summary: A new Nature study reveals that adult thymic health materially affects immune aging and responses to cancer treatment. Researchers show thymic integrity correlates with stronger immune surveillance and better therapy outcomes, reviving interest in thymus-targeted interventions. Experts describe the finding as a necessary reappraisal of an organ long written off by adult medicine — cue the applause.
- Aging immunity: why older immune systems fail us (5)
- Front lines: new targets and tactics in cancer immunotherapy (9)
- On the ground: adult thymus drives longevity and therapy success (5)
- All Other Stories
Aging immunity: why older immune systems fail us
Front lines: new targets and tactics in cancer immunotherapy
On the ground: adult thymus drives longevity and therapy success
All Other Stories
TerraPower Isotopes Invests $450M in Actinium-225 Production Facility
oncodaily - TerraPower Isotopes (TPI), the Bill Gates-founded nuclear science company, unveiled plans on March 17, 2026 to invest $450 million in a state-of-the-art actinium-225 (Ac-225) manufacturing facility in Philadelphia’s Bellwether District. The 250,000-square…
AI Summary: TerraPower announced a $450 million investment to construct a commercial Actinium‑225 production facility to supply alpha‑emitting radioisotopes for targeted cancer therapies. The plan tackles chronic supply shortages, strengthens domestic radiopharmaceutical capacity and positions the company at the center of growing demand for targeted‑alpha therapeutics — and yes, investors are watching.
What happens to your brain in nature? The neuroscience explained
medicalxpress - Have you ever felt calmer almost as soon as you step into the woods? Or maybe noticed your busy mind soften as you look out at the sea?
AI Summary: Researchers report that immersive time in natural settings produces detectable changes in brain networks tied to attention, emotion regulation and memory. The findings suggest brief nature exposure can recalibrate neural states and boost mental health — science’s polite way of telling you to go outside instead of doomscrolling.
Verily raises $300M, sheds Alphabet’s majority control
Shelby Livingston / endpoints - Verily has raised $300 million in new, outside funding that ends parent company Alphabet's controlling position in the healthcare innovation company, Endpoints News has learned exclusively. The funding round was led by Series X Capital ...
AI Summary: Verily secured a $300 million financing round that reduces Alphabet’s majority control, bringing new strategic investors on board including health system partners. The cash infusion aims to accelerate Verily’s healthcare technology and platform ambitions — because nothing says “healthcare disruption” like another well‑funded pivot.